Search company, investor...

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$152.82M

About Respicardia

Respicardia, formerly Cardiac Concepts, is developing implantable therapies designed to improve respiratory and cardiovascular health. The company's initial product, the remede System, is an implantable stimulation device designed to restore a more regular breathing pattern during sleep for central sleep apnea patients. On April 12th, 2021, Respicardia was acquired by ZOLL Medical Corporation. The terms of the transaction were not disclosed.

Headquarters Location

12400 Whitewater Dr Suite 150

Minnetonka, Minnesota, 55343,

United States

952-540-4470

Loading...

Loading...

Respicardia Patents

Respicardia has filed 26 patents.

The 3 most popular patent topics include:

  • abnormal respiration
  • sleep disorders
  • breathing abnormalities
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/17/2019

7/19/2022

Cardiac anatomy, Veins of the torso, Implants (medicine), Vascular diseases, Congenital heart defects

Grant

Application Date

12/17/2019

Grant Date

7/19/2022

Title

Related Topics

Cardiac anatomy, Veins of the torso, Implants (medicine), Vascular diseases, Congenital heart defects

Status

Grant

Latest Respicardia News

Sleep apnea hypoxic burden predicts cardiovascular disease, mortality

Aug 10, 2023

Disclosures: NHLBI, the National Center for Advancing Translational Sciences, the National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases partially supported this study. Azarbarzin reports receiving grant support from Somnifix and serving as a consultant for Apnimed, Respicardia and Somnifix. Apnimed is developing pharmacological treatments for obstructive sleep apnea. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Ventilatory burden explained around 75% of variation in hypoxic burden. Obstructive sleep apnea-related increases in hypoxic and ventilatory burdens heightened the risk for cardiovascular disease, according to results published in American Journal of Respiratory and Critical Care Medicine. Ali Azarbarzin “Obstructive sleep apnea is characterized by the frequent collapse of the upper airway leading to interrupted breathing (or lack of ventilation) during sleep,” Ali Azarbarzin, PhD, assistant professor of medicine in the division of sleep medicine at Harvard Medical School, told Healio. “These periods of interrupted breathing are often followed by drops in blood oxygen level and/or arousals from sleep. Current approaches do not quantify the magnitude of these breathing-related disturbances and therefore are limited to capture the risk of cardiovascular disease, for example. Data were derived from Labarca G, et al. Am J Respir Crit Care Med. 2023;doi:10.1164/rccm.202209-1808OC. “In this study, we attempted to better quantify the degree of interrupted breathing (‘ventilatory burden’), the total drop in blood oxygen level (‘hypoxic burden’) and the total duration of awakening (‘arousal burden’),” Azarbarzin added. Azarbarzin and colleagues evaluated baseline polysomnogram data of 1,973 adults (median age, 67 years; 46.4% men; 36.5% white) from the Multi-Ethnic Study of Atherosclerosis (MESA) study and 2,627 men (median age, 76 years; 90.7% white) from the Osteoporotic Fractures in Men (MrOS) study to understand how hypoxic burden , ventilatory burden and arousal burden are each related to incident CVD and mortality. Researchers also sought to find out how much variation in hypoxic burden was explained by ventilatory burden, baseline SpO2, visceral obesity and lung function measures. Compared with the MrOS cohort, the MESA cohort had a lower baseline hypoxic burden (43.8% min/hour vs. 37.5% min/hour), median ventilatory burden (457% eupnea × min/hour vs. 318% eupnea × min/hour) and arousal burden (7.5% sleep time vs. 7.2% sleep time). Median follow-up was 6.9 years in MESA and 9.4 years in MrOS. Within these periods, researchers observed 110 new primary cardiovascular events in MESA — including myocardial infarction, resuscitated cardiac arrest, stroke and death related to coronary heart disease or stroke, defined as incident hard CVD — and 382 new events, including congenital heart disease, cerebrovascular disease events, peripheral vascular disease, other cardiovascular disease events and any heart failure, in MrOS. In both cohorts, researchers found significant links between incident CVD and hypoxic and ventilatory burdens in Cox regression models adjusted for age, sex, race , BMI, hypertension, diabetes, smoking status and wake SpO2. Specifically, every one standard deviation increase in hypoxic burden was associated with a 45% (95% CI, 14%-84%) higher risk for incident hard CVD among adults in MESA, and a 13% (95% CI, 2%-26%) higher risk among men in the MrOS cohort. The risk for all-cause mortality also significantly increased with greater hypoxic burden in the MESA cohort (adjusted HR = 1.24; 95% CI, 1.05-1.47). The same rate of increase in ventilatory burden was linked to a 35% (95% CI, 9%-67%) greater risk for incident hard CVD in the MESA cohort and a 12% (95% CI, 1%-25%) greater risk in the MrOS cohort. Similar to hypoxic burden, ventilatory burden was significantly linked to all-cause mortality in the MESA cohort (aHR = 1.19; 95% CI, 1.02-1.4). Although all-cause mortality was not significantly linked to an increase in hypoxic burden or ventilatory burden following adjustments in the MrOS cohort, the risk for cardiovascular death was heightened with an increase in hypoxic burden (aHR = 1.24; 95% CI, 1.11-1.37) and ventilatory burden (aHR = 1.16; 95% CI, 1.05-1.28). “Hypoxic burden was the strongest and most consistent predictor of risk, confirming recent findings from our group and others,” Azarbarzin told Healio. Arousal burden was not significantly linked to cardiovascular disease in either cohort, which was an unexpected finding according to Azarbarzin. “In OSA, arousals are used to measure sleep fragmentation which in prior experimental studies was shown to be associated with elevated blood pressure; however, it is possible that the noise associated with measurement of arousals makes arousal-related metrics less precise,” he told Healio. Notably, exploratory analyses showed that ventilatory burden explained 78% of the variation in hypoxic burden in the model adjusted for age, race and BMI, and this continued to be found following adjustments for all variables, with ventilatory burden explaining 74% of hypoxic burden variation. In the fully adjusted model, BMI only explained 6% of variations in hypoxic burden whereas wakefulness SpO2 and race each only explained 2%, according to researchers. “These findings are based on secondary analysis of existing data,” Azarbarzin told Healio. “We need to confirm these findings in a randomized controlled trial in which these metrics are used to inform enrollment of participants into the trials.” Reference: NIH-funded study explains link to increased cardiovascular risks for people with obstructive sleep apnea. https://www.nih.gov/news-events/news-releases/nih-funded-study-explains-link-increased-cardiovascular-risks-people-obstructive-sleep-apnea . Published July 26, 2023. Accessed Aug. 1, 2023. For more information:

Respicardia Frequently Asked Questions (FAQ)

  • When was Respicardia founded?

    Respicardia was founded in 2006.

  • Where is Respicardia's headquarters?

    Respicardia's headquarters is located at 12400 Whitewater Dr, Minnetonka.

  • What is Respicardia's latest funding round?

    Respicardia's latest funding round is Acquired.

  • How much did Respicardia raise?

    Respicardia raised a total of $152.82M.

  • Who are the investors of Respicardia?

    Investors of Respicardia include ZOLL Medical, LivaNova, Accuitive Medical Ventures, Versant Ventures, Affinity Capital Management and 6 more.

  • Who are Respicardia's competitors?

    Competitors of Respicardia include CardioKinetix, CircuLite, MiCardia, Apnex Medical, Hemosphere and 7 more.

Loading...

Compare Respicardia to Competitors

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

B
Bio Control Medical

Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

C
CardioKinetix

CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.

C
CardioMetrix

CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

JenaValve Logo
JenaValve

JenaValve is a global medical device company focused on the healthcare sector, specifically in the domain of structural heart disease. The company's main offering is the development of innovative medical device technology, particularly transcatheter aortic valve replacement (TAVR) systems, designed to treat patients suffering from aortic valve disease. JenaValve primarily serves the healthcare industry, with a specific focus on cardiac care. It was founded in 2006 and is based in Irvine, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.